Oxidative folding of leech-derived tryptase inhibitor via native disulfide-bonded intermediates

Antioxidants and Redox Signaling

Volumn 10, Issue 1, 2008, Pages 77-85

  Arolas, Joan L ^a   Bronsoms, Sílvia ^a   Aviles, Francesc X ^a   Ventura, Salvador ^a   Sommerhoff, Christian P ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; LEECH DERIVED TRYPTASE INHIBITOR; TRYPTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DISULFIDE BOND; ISOMER; LEECH; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN STRUCTURE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISULFIDES; MASS SPECTROMETRY; MODELS, MOLECULAR; OXIDATIVE STRESS; PROTEIN FOLDING; PROTEINS; RECOMBINANT PROTEINS;

HIRUDINIDA;

EID: 36148952571     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1850     Document Type: Article

References (37)

1. Arolas JL, Aviles FX, Chang JY, and Ventura S. Folding of small disulfide-rich proteins: clarifying the puzzle. Trends Biochem Sci 31: 292-301, 2006.
2. Arolas JL, Bronsoms S, Lorenzo J, Aviles FX, Chang JY, and Ventura S. Role of kinetic intermediates in the folding of leech carboxypeptidase inhibitor. J Biol Chem 279: 37261-37270, 2004.
3. Auerswald EA, Morenweiser R, Sommerhoff CP, Piechottka GP, Eckerskorn C, Gurtler LG, and Fritz H. Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication. Biol Chem Hoppe Seyler 375: 695-703, 1994.
4. Creighton TE. Disulfide bonds as probes of protein folding pathways. Methods Enzymol 131: 83-106, 1986.
5. Creighton TE. The disulfide folding pathway of BPTI. Science 256: 111-114, 1992.
6. Chang J and Ballatore A. The structure of denatured bovine pancreatic trypsin inhibitor (BPTI). FEBS Lett 473: 183-187, 2000.
7. Chang JY. The disulfide folding pathway of tick anticoagulant peptide (TAP), a Kunitz-type inhibitor structurally homologous to BPTI. Biochemistry 35: 11702-11709, 1996.
8. Chang JY. A two-stage mechanism for the reductive unfolding of disulfide-containing proteins. J Biol Chem 272: 69-75, 1997.
9. Chang JY, Canals F, Schindler P, Querol E, and Aviles FX. The disulfide folding pathway of potato carboxypeptidase inhibitor. J Biol Chem 269: 22087-22094, 1994.
10. Chang JY, Li L, and Bulychev A. The underlying mechanism for the diversity of disulfide folding pathways. J Biol Chem 275: 8287-8289, 2000.
11. Chang JY, Li L, and Lai PH. A major kinetic trap for the oxidative folding of human epidermal growth factor. J Biol Chem 276: 4845-4852, 2001.
12. Chang JY, Lu BY, and Li L. Conformational impurity of disulfide proteins: detection, quantification, and properties. Anal Biochem 342: 78-85, 2005.
13. Chang JY, Schindler P, and Chatrenet B. The disulfide structures of scrambled hirudins. J Biol Chem 270: 11992-11997, 1995.
14. Chatrenet B and Chang JY. The disulfide folding pathway of hirudin elucidated by stop/go folding experiments. J Biol Chem 268: 20988-20996, 1993.
15. Daggett V and Fersht AR. Is there a unifying mechanism for protein folding? Trends Biochem Sci 28: 18-25, 2003.
16. Daly NL, Clark RJ, and Craik DJ. Disulfide folding pathways of cystine knot proteins: tying the knot within the circular backbone of the cyclotides. J Biol Chem 278: 6314-6322, 2003.
17. Darby NJ, Morin PE, Talbo G, and Creighton TE. Refolding of bovine pancreatic trypsin inhibitor via non-native disulphide intermediates. J Mol Biol 249: 463-477, 1995.
18. Di Marco S and Priestle JP. Structure of the complex of leech-derived tryptase inhibitor (LDTI) with trypsin and modeling of the LDTI-tryptase system. Structure 5: 1465-1474, 1997.
19. English BP, Welker E, Narayan M, and Scheraga HA. Development of a novel method to populate native disulfide-bonded intermediates for structural characterization of proteins: implications for the mechanism of oxidative folding of RNase A. J Am Chem Soc 124: 4995-4999, 2002.
20. Hallgren J and Pejler G. Biology of mast cell tryptase: an inflammatory mediator. FEBS J 273: 1871-1895, 2006.
21. Hemmi H, Kumazaki T, Yoshizawa-Kumagaye K, Nishiuchi Y, Yoshida T, Ohkubo T, and Kobayashi Y. Structural and functional study of an Anemonia elastase inhibitor, a "nonclassical" Kazaltype inhibitor from Anemonia sulcata. Biochemistry 44: 9626-9636, 2005.
22. Hemmi H, Yoshida T, Kumazaki T, Nemoto N, Hasegawa J, Nishioka F, Kyogoku Y, Yokosawa H, and Kobayashi Y. Solution structure of ascidian trypsin inhibitor determined by nuclear magnetic resonance spectroscopy. Biochemistry 41: 10657-10664, 2002.
23. Morenweiser R, Auerswald EA, van de Locht A, Fritz H, Sturzebecher J, and Stubbs MT. Structure-based design of a potent chimeric thrombin inhibitor. J Biol Chem 272: 19938-19942, 1997.
24. Muhlhahn P, Czisch M, Morenweiser R, Habermann B, Engh RA, Sommerhoff CP, Auerswald EA, and Holak TA. Structure of leech derived tryptase inhibitor (LDTI-C) in solution. FEBS Lett 355: 290-296, 1994.
25. Onuchic JN and Wolynes PG. Theory of protein folding. Curr Opin Struct Biol 14: 70-75, 2004.
26. Pohlig G, Fendrich G, Knecht R, Eder B, Piechottka G, Sommerhoff CP, and Heim J. Purification, characterization and biological evaluation of recombinant leech-derived tryptase inhibitor (rLDTI) expressed at high level in the yeast Saccharomyces cerevisiae. Eur J Biochem 241: 619-626, 1996.
27. Radford SE, Dobson CM, and Evans PA. The folding of hen lysozyme involves partially structured intermediates and multiple pathways. Nature 358: 302-307, 1992.
28. Ross CA and Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 10(suppl): S10-S17, 2004.
29. Sanchez de Groot N, Pallares I, Aviles FX, Vendrell J, and Ventura S. Prediction of "hot spots" of aggregation in disease-linked polypeptides. BMC Struct Biol 5: 18, 2005.
30. Scheraga HA, Konishi Y, Rothwarf DM, and Mui PW. Toward an understanding of the folding of ribonuclease A. Proc Natl Acad Sci U S A 84: 5740-5744, 1987.
31. Sommerhoff CP. Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 164: S52-S58, 2001.
32. Sommerhoff CP and Schaschke N. Mast cell tryptase beta as a target in allergic inflammation: an evolving story. Curr Pharm Des 13: 313-332, 2007.
33. Sommerhoff CP, Sollner C, Mentele R, Piechottka GP, Auerswald EA, and Fritz H. A Kazal-type inhibitor of human mast cell tryptase: isolation from the medical leech Hirudo medicinalis, characterization, and sequence analysis. Biol Chem Hoppe Seyler 375: 685-694, 1994.
34. Stubbs MT, Morenweiser R, Sturzebecher J, Bauer M, Bode W, Huber R, Piechottka GP, Matschiner G, Sommerhoff CP, Fritz H, and Auerswald EA. The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin: implications for the structure of human mast cell tryptase and its inhibition. J Biol Chem 272: 19931-19937, 1997.
35. Thannhauser TW, McWherter CA, and Scheraga HA. Peptide mapping of bovine pancreatic ribonuclease A by reverse-phase high-performance liquid chromatography, II: a two-dimensional technique for determination of disulfide pairings using a continuous-flow disulfide-detection system. Anal Biochem 149: 322-330, 1985.
36. Weissman JS and Kim PS. Reexamination of the folding of BPTI: predominance of native intermediates. Science 253: 1386-1393, 1991.
37. Welker E, Narayan M, Wedemeyer WJ, and Scheraga HA. Structural determinants of oxidative folding in proteins. Proc Natl Acad Sci U S A 98: 2312-2316, 2001.